We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000623
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : March 4, 2014
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Information provided by:

Brief Summary:
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.

Condition or disease Intervention/treatment
Anemia, Cooley's Beta-Thalassemia Hematologic Diseases Thalassemia Osteoporosis Iron Overload Hypertension, Pulmonary Drug: Deferoxamine Drug: Deferiprone Drug: Arginine Drug: Sildenafil Drug: Decitabine

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Time Perspective: Prospective
Official Title: Thalassemia Clinical Research Network (TCRN)
Study Start Date : July 2000
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thalassemia

Primary Outcome Measures :
  1. Vary by protocol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Please refer to specific studies for eligibility criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000623

Layout table for location information
United States, California
Children's Hospital Oakland
Oakland, California, United States, 94609
United States, Massachusetts
Children's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
Weill Medical College of Cornell University
New York, New York, United States, 10021
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Layout table for investigator information
Principal Investigator: Alan R. Cohen, MD Children's Hospital of Philadelphia
Principal Investigator: Patricia J. Giardina, MD Weill Medical College of Cornell University
Principal Investigator: Ellis J. Neufeld, MD, PhD Children's Hospital Medical Center, Cincinnati
Principal Investigator: Nancy F. Olivieri, MD Toronto General Hospital
Principal Investigator: Elliott P. Vichinsky, MD UCSF Benioff Children's Hospital Oakland
Principal Investigator: Sonja McKinlay, PhD New England Research Institutes, Inc.
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00000623    
Other Study ID Numbers: 317
U01HL065232 ( U.S. NIH Grant/Contract )
U01HL065233 ( U.S. NIH Grant/Contract )
U01HL065238 ( U.S. NIH Grant/Contract )
U01HL065239 ( U.S. NIH Grant/Contract )
U01HL065244 ( U.S. NIH Grant/Contract )
U01HL065260 ( U.S. NIH Grant/Contract )
First Posted: October 28, 1999    Key Record Dates
Last Update Posted: March 4, 2014
Last Verified: July 2006
Keywords provided by HealthCore-NERI:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Hematologic Diseases
Iron Overload
Vascular Diseases
Cardiovascular Diseases
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Genetic Diseases, Inborn
Iron Metabolism Disorders
Lung Diseases
Respiratory Tract Diseases
Sildenafil Citrate
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors